Denali Therapeutics (DNLI) Enterprise Value (2017 - 2025)
Denali Therapeutics (DNLI) has disclosed Enterprise Value for 9 consecutive years, with -$867.9 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 4.27% to -$867.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$867.9 million through Dec 2025, down 4.27% year-over-year, with the annual reading at -$867.9 million for FY2025, 4.27% down from the prior year.
- Enterprise Value for Q4 2025 was -$867.9 million at Denali Therapeutics, down from -$848.2 million in the prior quarter.
- The five-year high for Enterprise Value was -$817.9 million in Q1 2025, with the low at -$1.4 billion in Q1 2021.
- Average Enterprise Value over 5 years is -$1.0 billion, with a median of -$996.0 million recorded in 2022.
- Peak annual rise in Enterprise Value hit 41.12% in 2021, while the deepest fall reached 140.64% in 2021.
- Over 5 years, Enterprise Value stood at -$865.4 million in 2021, then crashed by 54.4% to -$1.3 billion in 2022, then increased by 22.58% to -$1.0 billion in 2023, then grew by 19.54% to -$832.3 million in 2024, then decreased by 4.27% to -$867.9 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$867.9 million, -$848.2 million, and -$899.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.